Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
P 2 (1)
P 3 (1)

Trial Status

Active Not Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT02375204Phase 3Active Not Recruiting

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

NCT01808534Phase 2Terminated

Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

Showing all 2 trials

Research Network

Activity Timeline